Menu Search
Equities

Alpha Tau Medical Ltd

DRTS:NAQ

Alpha Tau Medical Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.27
  • Today's Change0.025 / 1.12%
  • Shares traded2.05k
  • 1 Year change-27.17%
  • Beta0.7569
Data delayed at least 15 minutes, as of Nov 08 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 4 analysts offering 12 month price targets for Alpha Tau Medical Ltd have a median target of 8.50, with a high estimate of 13.00 and a low estimate of 7.00. The median estimate represents a 275.28% increase from the last price of 2.27.
High474.0%13.00
Med275.3%8.50
Low209.1%7.00

Earnings history & estimates in USD

On Aug 14, 2024, Alpha Tau Medical Ltd reported 2nd quarter 2024 losses of -0.11 per share. This result exceeded the -0.13 consensus loss of the 2 analysts covering the company and exceeded last year's 2nd quarter results by 8.33%.
The next earnings announcement is expected on Nov 19, 2024.
Average growth rate-3.87%
Alpha Tau Medical Ltd reported annual 2023 losses of -0.42 per share on Mar 07, 2024.
Average growth rate+20.83%
More ▼

Revenue history & estimates in USD

Alpha Tau Medical Ltd did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Alpha Tau Medical Ltd did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.